Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 31;17(7):1192.
doi: 10.3390/cancers17071192.

The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL

Austin Kordic  1 , Tycel Jovelle Phillips  1 , Jonathan Weiss  2
Affiliations
Review

The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL

Austin Kordic et al. Cancers (Basel). .

Abstract

Relapsed/refractory non-Hodgkin lymphoma (r/r/NHL) is an aggressive disease with overall poor response rates to chemo-immunotherapy and autologous stem-cell transplant, especially in patients with diffuse large B-cell lymphoma. Major improvements in this disease space have come through the incorporation of novel immune therapies, including CD19/CD20 directed CAR-T cells and bispecific antibodies. These exciting new therapies continue to change the landscape of treatment for r/r NHL and have been incorporated in earlier lines of therapy with demonstrated efficacy and patient safety. In this review, the role of these treatments in the management of relapsed/refractory NHL is discussed in detail along with future directions of research.

Keywords: CAR-T cell therapy; bispecific antibodies (BsAbs); diffuse large B-cell Lymphoma (DLBCL); follicular lymphoma (FL); immunotherapy; mantle cell Lymphoma (MCL); non-Hodgkin’s Lymphoma (NHL); relapsed/refractory lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Crump M., Neelapu S.S., Farooq U., Van Den Neste E., Kuruvilla J., Westin J., Link B.K., Hay A., Cerhan J.R., Zhu L., et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 2017;130:1800–1808. doi: 10.1182/blood-2017-03-769620. - DOI - PMC - PubMed
    1. Philip T., Guglielmi C., Hagenbeek A., Somers R., Van der Lelie H., Bron D., Sonneveld P., Gisselbrecht C., Cahn J.Y., Harousseau J.L., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N. Engl. J. Med. 1995;333:1540–1545. doi: 10.1056/nejm199512073332305. - DOI - PubMed
    1. Coiffier B., Haioun C., Ketterer N., Engert A., Tilly H., Ma D., Johnson P., Lister A., Feuring-Buske M., Radford J.A., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood. 1998;92:1927–1932. - PubMed
    1. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Fermé C., Christian B., Lepage E., Tilly H., Morschhauser F., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol. 2005;23:4117–4126. doi: 10.1200/jco.2005.09.131. - DOI - PubMed
    1. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002;346:235–242. doi: 10.1056/NEJMoa011795. - DOI - PubMed

LinkOut - more resources